Xiang H - Search Results

1

Clinicopathological analysis of early-stage breast cancer patients that meet indications for BRCA1/2 genetic testing.

Xiang H, Xin L, Liu Q, Zhang H, Zhang S, Ye J, Cheng Y, Li T, Liu Y, Xu L. Xiang H, et al. Chin J Cancer Res. 2020 Apr;32(2):163-174. doi: 10.21147/j.issn.1000-9604.2020.02.04. Chin J Cancer Res. 2020. PMID: 32410794 Free PMC article.

2

[Study on the epidemiological characteristics of diabetes mellitus and IGT in China].

Wang K, Li T, Xiang H. Wang K, et al. Among authors: xiang h. Zhonghua Liu Xing Bing Xue Za Zhi. 1998 Oct;19(5):282-5. Zhonghua Liu Xing Bing Xue Za Zhi. 1998. PMID: 10322687 Clinical Trial. Chinese.

3

Clinicopathologic analysis of 722 breast cancer patients who met the inclusion criteria of the TAILORx trial.

Xiang HY, Liu YH, Zhang H, Zhang S, Xin L, Xu L, Ye JM, Li T, Duan XN, Liu Q. Xiang HY, et al. Chin Med J (Engl). 2019 Dec 20;132(24):2914-2919. doi: 10.1097/CM9.0000000000000548. Chin Med J (Engl). 2019. PMID: 31809316 Free PMC article.

4

Retrospective analysis of sentinel lymph node biopsy using methylene blue dye for early breast cancer.

Yang S, Xiang HY, Xin L, Zhang H, Zhang S, Cheng YJ, Liu Q, Xu L, Li T, Duan XN, Ye JM, Liu YH. Yang S, et al. Among authors: xiang hy. Chin Med J (Engl). 2021 Jan 11;134(3):318-325. doi: 10.1097/CM9.0000000000001359. Chin Med J (Engl). 2021. PMID: 33522727 Free PMC article.

5

Multicenter study of the clinicopathological features and recurrence risk prediction model of early-stage breast cancer with low-positive human epidermal growth factor receptor 2 expression in China (Chinese Society of Breast Surgery 021).

Xin L, Wu Q, Zhan C, Qin H, Xiang H, Xu L, Ye J, Duan X, Liu Y; Chinese Society of Breast Surgery (CSBrS), Chinese Society of Surgery of Chinese Medical Association. Xin L, et al. Among authors: xiang h. Chin Med J (Engl). 2022 Mar 20;135(6):697-706. doi: 10.1097/CM9.0000000000002056. Chin Med J (Engl). 2022. PMID: 35274907 Free PMC article.

6

Neoadjuvant therapy for early human epidermal growth factor receptor 2 positive breast cancer in China: A multicenter real-world study (CSBrS-015).

Cheng Y, Xiang H, Xin L, Duan X, Liu Y; Chinese Society of Breast Surgery (CSBrS), Chinese Society of Surgery of Chinese Medical Association. Cheng Y, et al. Among authors: xiang h. Chin Med J (Engl). 2022 Oct 5;135(19):2311-2318. doi: 10.1097/CM9.0000000000002197. Chin Med J (Engl). 2022. PMID: 36535009 Free PMC article.

7

Correlation between Androgen Receptor Expression in Luminal B (HER-2 Negative) Breast Cancer and Disease Outcomes.

Yang F, Li J, Zhang H, Zhang S, Ye J, Cheng Y, Liu Q, Xin L, Xiang H, Liu Y, Duan X, Xu L. Yang F, et al. Among authors: xiang h. J Pers Med. 2022 Dec 1;12(12):1988. doi: 10.3390/jpm12121988. J Pers Med. 2022. PMID: 36556209 Free PMC article.

8

Comparison of adverse effects of anti-tumor therapy for breast cancer shortly after COVID-19 diagnosis vs. the control period.

Ding M, Xiang H, Ye J, Cheng Y, Liu Q, Xu L. Ding M, et al. Among authors: xiang h. Front Oncol. 2023 Aug 21;13:1203119. doi: 10.3389/fonc.2023.1203119. eCollection 2023. Front Oncol. 2023. PMID: 37671052 Free PMC article.

9

A multicenter study of the clinicopathological characteristics and a risk prediction model of early-stage breast cancer with hormone receptor-positive/human epidermal growth factor receptor 2-low expression.

Xin L, Wu Q, Zhan C, Qin H, Xiang H, Gao M, Duan X, Liu Y, Ye J; Chinese Society of Breast Surgery (CSBrS); Chinese Society of Surgery of Chinese Medical Association. Xin L, et al. Among authors: xiang h. Chin Med J (Engl). 2023 Dec 20;136(24):2967-2973. doi: 10.1097/CM9.0000000000002831. Epub 2023 Oct 11. Chin Med J (Engl). 2023. PMID: 37822006 Free PMC article.

10

A multicenter study on efficacy of dual-target neoadjuvant therapy for HER2-positive breast cancer and a consistent analysis of efficacy evaluation of neoadjuvant therapy by Miller-Payne and RCB pathological evaluation systems (CSBrS-026).

Xiang H, Xin L, Ye J, Xu L, Zhang H, Zhang S, Liu Y. Xiang H, et al. Chin J Cancer Res. 2023 Dec 30;35(6):702-712. doi: 10.21147/j.issn.1000-9604.2023.06.13. Chin J Cancer Res. 2023. PMID: 38204446 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,606 results

Search Page

Filters